Second Sight Medical Products Inc. (NASDAQ:EYES) shares traded down 1.2% on Friday . The stock traded as low as $3.96 and last traded at $4.05, with a volume of 492,095 shares. The stock had previously closed at $4.10.

Separately, Zacks Investment Research lowered shares of Second Sight Medical Products from a “hold” rating to a “sell” rating in a research report on Tuesday, April 26th.

The stock has a 50 day moving average of $3.78 and a 200-day moving average of $4.63. The firm’s market capitalization is $146.31 million.

Second Sight Medical Products (NASDAQ:EYES) last announced its quarterly earnings data on Thursday, April 28th. The medical device company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.03. The business earned $1.05 million during the quarter, compared to analyst estimates of $1.38 million. The business’s revenue for the quarter was down 38.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.12) EPS. On average, equities research analysts forecast that Second Sight Medical Products Inc. will post ($0.65) EPS for the current fiscal year.

In other news, Chairman Robert J. Greenberg sold 8,571 shares of Second Sight Medical Products stock in a transaction that occurred on Thursday, June 2nd. The shares were sold at an average price of $4.10, for a total value of $35,141.10. Following the transaction, the chairman now directly owns 172,911 shares of the company’s stock, valued at $708,935.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Chairman Robert J. Greenberg sold 8,223 shares of Second Sight Medical Products stock in a transaction that occurred on Monday, April 18th. The stock was sold at an average price of $5.27, for a total transaction of $43,335.21. Following the completion of the transaction, the chairman now directly owns 181,134 shares in the company, valued at $954,576.18. The disclosure for this sale can be found here.

A hedge fund recently bought a new stake in Second Sight Medical Products stock. Zeke Capital Advisors LLC bought a new stake in Second Sight Medical Products Inc. (NASDAQ:EYES) during the fourth quarter, Holdings Channel reports. The institutional investor bought 496,428 shares of the medical device company’s stock, valued at approximately $2,924,000. Second Sight Medical Products accounts for approximately 2.5% of Zeke Capital Advisors LLC’s investment portfolio, making the stock its 10th largest position. Zeke Capital Advisors LLC owned approximately 1.38% of Second Sight Medical Products at the end of the most recent reporting period.

Second Sight Medical Products, Inc is a medical device company that develops, manufactures and markets implantable visual prosthetics to restore some functional vision to blind patients. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.